SRP426514 Track Settings
 
Epigenetic therapy activates TE-chimeric transcripts to provide additional source of antigens in glioblastoma stem cells [Astrocytes, Glioblastoma Stem Cell, Primary Dermal Fibroblast]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
SRX19626981 
SRX19626982 
SRX19626983 
SRX19626984 
SRX19626985 
SRX19626986 
SRX19626987 
SRX19626988 
SRX19626989 
SRX19626990 
SRX19626991 
SRX19626992 
SRX19626993 
SRX19626994 
SRX19626995 
SRX19626996 
SRX19626997 
SRX19626998 
SRX19626999 
SRX19627000 
SRX19627001 
SRX19627002 
SRX19627003 
SRX19627004 
SRX19627005 
SRX19627006 
SRX19627007 
SRX19627030 
experiment
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX19626997  HMR  Astrocytes / SRX19626997 (HMR)   schema 
hide
 SRX19626981  CpG methylation  Glioblastoma Stem Cell / SRX19626981 (CpG methylation)   schema 
hide
 SRX19626998  HMR  Astrocytes / SRX19626998 (HMR)   schema 
hide
 SRX19626982  CpG methylation  Glioblastoma Stem Cell / SRX19626982 (CpG methylation)   schema 
hide
 SRX19626999  HMR  Astrocytes / SRX19626999 (HMR)   schema 
hide
 SRX19626983  CpG methylation  Glioblastoma Stem Cell / SRX19626983 (CpG methylation)   schema 
hide
 SRX19627000  HMR  Astrocytes / SRX19627000 (HMR)   schema 
hide
 SRX19626984  CpG methylation  Glioblastoma Stem Cell / SRX19626984 (CpG methylation)   schema 
hide
 SRX19627005  HMR  Astrocytes / SRX19627005 (HMR)   schema 
hide
 SRX19626985  CpG methylation  Glioblastoma Stem Cell / SRX19626985 (CpG methylation)   schema 
hide
 SRX19627006  HMR  Astrocytes / SRX19627006 (HMR)   schema 
hide
 SRX19626986  CpG methylation  Glioblastoma Stem Cell / SRX19626986 (CpG methylation)   schema 
hide
 SRX19627007  HMR  Astrocytes / SRX19627007 (HMR)   schema 
hide
 SRX19626987  CpG methylation  Glioblastoma Stem Cell / SRX19626987 (CpG methylation)   schema 
hide
 SRX19627030  HMR  Astrocytes / SRX19627030 (HMR)   schema 
hide
 SRX19626988  CpG methylation  Glioblastoma Stem Cell / SRX19626988 (CpG methylation)   schema 
hide
 SRX19626989  CpG methylation  Glioblastoma Stem Cell / SRX19626989 (CpG methylation)   schema 
hide
 SRX19626990  CpG methylation  Glioblastoma Stem Cell / SRX19626990 (CpG methylation)   schema 
hide
 SRX19626991  CpG methylation  Glioblastoma Stem Cell / SRX19626991 (CpG methylation)   schema 
hide
 SRX19626992  CpG methylation  Glioblastoma Stem Cell / SRX19626992 (CpG methylation)   schema 
hide
 SRX19626993  CpG methylation  Primary Dermal Fibroblast / SRX19626993 (CpG methylation)   schema 
hide
 SRX19626994  CpG methylation  Primary Dermal Fibroblast / SRX19626994 (CpG methylation)   schema 
hide
 SRX19626995  CpG methylation  Primary Dermal Fibroblast / SRX19626995 (CpG methylation)   schema 
hide
 SRX19626996  CpG methylation  Primary Dermal Fibroblast / SRX19626996 (CpG methylation)   schema 
hide
 SRX19626997  CpG methylation  Astrocytes / SRX19626997 (CpG methylation)   schema 
hide
 SRX19626998  CpG methylation  Astrocytes / SRX19626998 (CpG methylation)   schema 
hide
 SRX19626999  CpG methylation  Astrocytes / SRX19626999 (CpG methylation)   schema 
hide
 SRX19627000  CpG methylation  Astrocytes / SRX19627000 (CpG methylation)   schema 
hide
 SRX19627001  CpG methylation  Primary Dermal Fibroblast / SRX19627001 (CpG methylation)   schema 
hide
 SRX19627002  CpG methylation  Primary Dermal Fibroblast / SRX19627002 (CpG methylation)   schema 
hide
 SRX19627003  CpG methylation  Primary Dermal Fibroblast / SRX19627003 (CpG methylation)   schema 
hide
 SRX19627004  CpG methylation  Primary Dermal Fibroblast / SRX19627004 (CpG methylation)   schema 
hide
 SRX19627005  CpG methylation  Astrocytes / SRX19627005 (CpG methylation)   schema 
hide
 SRX19627006  CpG methylation  Astrocytes / SRX19627006 (CpG methylation)   schema 
hide
 SRX19627007  CpG methylation  Astrocytes / SRX19627007 (CpG methylation)   schema 
hide
 SRX19627030  CpG methylation  Astrocytes / SRX19627030 (CpG methylation)   schema 
    

Study title: Epigenetic therapy activates TE-chimeric transcripts to provide additional source of antigens in glioblastoma stem cells
SRA: SRP426514
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX19626981 Glioblastoma Stem Cell 0.431 5.3 26066 21444.1 93 859.5 2082 459867.6 0.992 GSM7090805: B36 cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19626982 Glioblastoma Stem Cell 0.433 6.5 36266 16816.3 1779 856.0 1931 474455.8 0.976 GSM7090806: B36 cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19626983 Glioblastoma Stem Cell 0.620 7.3 62669 11394.7 115 1039.7 2595 404866.2 0.991 GSM7090807: B36 cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19626984 Glioblastoma Stem Cell 0.644 9.2 70658 10438.4 219 980.8 2609 403203.9 0.991 GSM7090808: B36 cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19626985 Glioblastoma Stem Cell 0.228 4.1 0 0.0 2595 866.8 50 6607789.3 0.994 GSM7090809: B49 cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19626986 Glioblastoma Stem Cell 0.243 6.0 3200 58331.9 12924 1014.1 52 3762348.9 0.996 GSM7090810: B49 cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19626987 Glioblastoma Stem Cell 0.621 7.6 56049 12684.8 202 1272.7 2777 348809.7 0.996 GSM7090811: B49 cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19626988 Glioblastoma Stem Cell 0.616 7.5 57665 12308.0 210 1052.8 2774 350500.2 0.995 GSM7090812: B49 cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19626989 Glioblastoma Stem Cell 0.395 6.3 26951 21467.3 285 841.7 2062 468145.8 0.994 GSM7090813: B66 cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19626990 Glioblastoma Stem Cell 0.611 6.3 59317 12968.8 78 996.6 2228 482562.7 0.995 GSM7090814: B66 cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19626991 Glioblastoma Stem Cell 0.574 4.6 47967 14908.0 37 1173.3 2020 533685.2 0.995 GSM7090815: B66 cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19626992 Glioblastoma Stem Cell 0.318 5.6 10085 33928.4 5700 918.4 1884 476559.4 0.993 GSM7090816: B66 cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19626993 Primary Dermal Fibroblast 0.556 3.5 33892 12402.3 29 1090.5 1107 1015706.5 0.989 GSM7090817: hFB cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19626994 Primary Dermal Fibroblast 0.552 5.9 37606 13388.7 55 1057.5 1295 875925.3 0.988 GSM7090818: hFB cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19626995 Primary Dermal Fibroblast 0.640 6.1 56652 9603.2 37 1201.6 1654 729059.6 0.992 GSM7090819: hFB cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19626996 Primary Dermal Fibroblast 0.651 9.2 64924 8501.5 55 1052.7 1758 681565.5 0.986 GSM7090820: hFB cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19626997 Astrocytes 0.648 11.1 48967 1140.0 1116 854.5 2204 12474.2 0.997 GSM7090821: NHA cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19626998 Astrocytes 0.653 10.4 46923 1185.0 854 846.6 2075 12661.0 0.996 GSM7090822: NHA cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19626999 Astrocytes 0.766 8.9 49714 1172.3 720 892.4 1596 35211.8 0.997 GSM7090823: NHA cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19627000 Astrocytes 0.777 8.7 49601 1203.0 487 898.9 1537 37208.1 0.997 GSM7090824: NHA cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19627001 Primary Dermal Fibroblast 0.601 6.0 47853 13086.3 32 1158.5 1665 703980.4 0.994 GSM7090825: qhFB cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19627002 Primary Dermal Fibroblast 0.606 13.0 67524 9656.2 119 976.6 2217 523677.8 0.994 GSM7090826: qhFB cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19627003 Primary Dermal Fibroblast 0.655 3.5 47982 12322.4 12 976.8 1583 746067.1 0.994 GSM7090827: qhFB cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19627004 Primary Dermal Fibroblast 0.656 17.9 77902 8441.3 224 977.5 2330 512290.5 0.994 GSM7090828: qhFB cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq
SRX19627005 Astrocytes 0.776 8.2 46640 1467.8 80 948.2 1314 47018.3 0.991 GSM7090829: qNHA cells, WGBS, DACPano, BR1; Homo sapiens; Bisulfite-Seq
SRX19627006 Astrocytes 0.769 6.2 42953 1557.0 50 1061.3 1317 43045.2 0.991 GSM7090830: qNHA cells, WGBS, DACPano, BR2; Homo sapiens; Bisulfite-Seq
SRX19627007 Astrocytes 0.790 5.8 39579 1645.4 44 1042.4 1126 83280.7 0.992 GSM7090831: qNHA cells, WGBS, DMSO, BR1; Homo sapiens; Bisulfite-Seq
SRX19627030 Astrocytes 0.784 4.5 35951 1692.0 24 1297.8 1044 75652.0 0.991 GSM7090832: qNHA cells, WGBS, DMSO, BR2; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.